JP2018537536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537536A5 JP2018537536A5 JP2018549407A JP2018549407A JP2018537536A5 JP 2018537536 A5 JP2018537536 A5 JP 2018537536A5 JP 2018549407 A JP2018549407 A JP 2018549407A JP 2018549407 A JP2018549407 A JP 2018549407A JP 2018537536 A5 JP2018537536 A5 JP 2018537536A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- therapeutic composition
- cells
- composition according
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 201000011510 cancer Diseases 0.000 claims 13
- 230000001225 therapeutic effect Effects 0.000 claims 12
- 210000000822 natural killer cell Anatomy 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000012830 cancer therapeutic Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 102000004243 Tubulin Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265382P | 2015-12-09 | 2015-12-09 | |
| US62/265,382 | 2015-12-09 | ||
| PCT/US2016/066018 WO2017100709A1 (en) | 2015-12-09 | 2016-12-09 | Compositions and methods for treatment of her2 positive metastatic breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018537536A JP2018537536A (ja) | 2018-12-20 |
| JP2018537536A5 true JP2018537536A5 (cg-RX-API-DMAC7.html) | 2019-12-12 |
Family
ID=59013368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549407A Pending JP2018537536A (ja) | 2015-12-09 | 2016-12-09 | Ｈｅｒ２陽性転移性乳癌の治療のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180360881A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3386522A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018537536A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180123214A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109475576A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016366677A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3007996A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017100709A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4596053A3 (en) | 2016-07-15 | 2025-10-15 | Viracta Subsidiary, Inc. | Hdac inhibitors for use with nk cell based therapies |
| US20200197533A1 (en) * | 2017-06-22 | 2020-06-25 | University Of Southern California | Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers |
| CA3073045A1 (en) * | 2017-08-15 | 2019-02-21 | Nantcell, Inc. | Hank cetuximab combinations and methods |
| CN110484507B (zh) * | 2018-01-31 | 2023-10-13 | 温州医科大学 | 一种靶向肿瘤Her2的新型嵌合抗原受体T细胞的制备技术 |
| IL321548A (en) | 2018-05-22 | 2025-08-01 | Immunitybio Inc | Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof |
| EP3834843A4 (en) * | 2018-08-06 | 2022-05-11 | Daiichi Sankyo Company, Limited | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR |
| IL316199A (en) * | 2018-10-31 | 2024-12-01 | Immunitybio Inc | Clearance of PD-L1-positive malignancies by NK cells expressing a chimeric PD-L1 antigen receptor |
| KR20220041850A (ko) * | 2019-07-26 | 2022-04-01 | 난트퀘스트, 인크. | 종양 용해를 위한 효과적인 치료 산물로서의 항체 사전 로드된 cd16+nk-92 세포 |
| AU2021305084A1 (en) | 2020-07-07 | 2023-02-02 | Cancure, Llc | MIC antibodies and binding agents and methods of using the same |
| CN112675313A (zh) * | 2020-12-28 | 2021-04-20 | 烟台大学 | 连接曲妥珠单抗片段的美登素纳米粒组合物 |
| CN114807237A (zh) * | 2022-05-12 | 2022-07-29 | 广东普罗凯融生物医药科技有限公司 | 一种过表达CD16a的NK细胞的制备方法及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003072040A2 (en) * | 2002-02-25 | 2003-09-04 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
| WO2006072626A1 (en) * | 2005-01-06 | 2006-07-13 | Novo Nordisk A/S | Kir-binding agents and methods of use thereof |
| US9296816B2 (en) * | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| EP2161339A1 (en) * | 2008-08-29 | 2010-03-10 | F. Hoffmann-La Roche Ag | ADCC with modified NK92 cells |
| EP3062800B1 (en) * | 2013-11-01 | 2020-04-08 | Nantkwest, Inc. | Tumoricidal compositions |
| AU2015235852B2 (en) * | 2014-03-28 | 2019-08-15 | Regents Of The University Of Minnesota | Polypeptides, cells, and methods involving engineered CD16 |
| JP2018509459A (ja) * | 2015-03-27 | 2018-04-05 | ナントクエスト インコーポレイテッド | がん治療薬との併用療法におけるｎｋ−９２細胞 |
-
2016
- 2016-12-09 CA CA3007996A patent/CA3007996A1/en active Pending
- 2016-12-09 US US15/781,428 patent/US20180360881A1/en not_active Abandoned
- 2016-12-09 WO PCT/US2016/066018 patent/WO2017100709A1/en not_active Ceased
- 2016-12-09 CN CN201680080518.8A patent/CN109475576A/zh active Pending
- 2016-12-09 AU AU2016366677A patent/AU2016366677A1/en not_active Abandoned
- 2016-12-09 JP JP2018549407A patent/JP2018537536A/ja active Pending
- 2016-12-09 EP EP16874010.8A patent/EP3386522A4/en not_active Withdrawn
- 2016-12-09 KR KR1020187019391A patent/KR20180123214A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537536A5 (cg-RX-API-DMAC7.html) | ||
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| Dagar et al. | Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments | |
| Luo et al. | Progress and prospect of immunotherapy for triple-negative breast cancer | |
| Herrera et al. | Bispecific antibodies: advancing precision oncology | |
| Park et al. | Targets and antibody formats for immunotherapy of neuroblastoma | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Dees et al. | Bispecific antibodies for triple negative breast cancer | |
| Majzner et al. | Harnessing the immunotherapy revolution for the treatment of childhood cancers | |
| Huehls et al. | Bispecific T‐cell engagers for cancer immunotherapy | |
| JP2019513777A5 (cg-RX-API-DMAC7.html) | ||
| Zhu et al. | Multifunctional receptor-targeting antibodies for cancer therapy | |
| Vyas et al. | Antigen loss variants: catching hold of escaping foes | |
| JP2017507936A5 (cg-RX-API-DMAC7.html) | ||
| Attarwala | Role of antibodies in cancer targeting | |
| JP2018529327A5 (cg-RX-API-DMAC7.html) | ||
| Shabaneh et al. | Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity | |
| JP2017537972A5 (cg-RX-API-DMAC7.html) | ||
| Patriarca et al. | Investigational drugs for the treatment of diffuse large B-cell lymphoma | |
| JP2016187356A5 (cg-RX-API-DMAC7.html) | ||
| JP2016513458A5 (cg-RX-API-DMAC7.html) | ||
| Ordóñez-Reyes et al. | Bispecific antibodies in cancer immunotherapy: a novel response to an old question | |
| JP2015517470A5 (cg-RX-API-DMAC7.html) | ||
| CA3079747A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| Kamakura et al. | T cell bispecific antibodies: an antibody-based delivery system for inducing antitumor immunity |